The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients.
Authorized common shares rise from 150,000,000. The August 5, 2026 special meeting also approved an amendment to the 2021 Stock Option and Incentive Plan.
Aura Biosciences agreed to buy back up to 6,922,870 shares from Matrix Capital at $5.64, the price of an equity offering it announced on May 4, 2026. The buyback comes out of the offering's proceeds, and the company put preliminary cash at $114.7 million as of March 31, 2026.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $67.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Aura Biosciences
Has Aura Biosciences raised money recently?
Our latest story on this, dated May 4, 2026: "Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price". The story links the filing or release it is based on. Read the story.
Does Aura Biosciences have a share buyback?
Our latest story on this, dated May 4, 2026: "Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Aura Biosciences?
Aura Biosciences, Inc. trades under the ticker AURA on NASDAQ.
Where is Aura Biosciences listed?
Aura Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of Aura Biosciences?
The SEC Central Index Key (CIK) for Aura Biosciences, Inc. is 1501796. Its filings are on SEC EDGAR.
How many shares does Aura Biosciences have outstanding?
103,704,809 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Aura Biosciences listed under?
Our directory records Aura Biosciences, Inc. under United States.
What does Aura Biosciences do?
Our directory classifies Aura Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Aura Biosciences?
The ISIN recorded for Aura Biosciences, Inc. is US05153U1079.
Does aibio.space cover Aura Biosciences?
aibio.space lists Aura Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Aura Biosciences incorporated?
SEC records list its state or country of incorporation as DE.
Is Aura Biosciences profitable?
Aura Biosciences, Inc. reported a net loss of $106.2 million for the fiscal year ended Dec 31, 2025, and used $84.7 million of cash in operations, per its annual report to the SEC.
How much does Aura Biosciences spend on research and development?
$90.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Aura Biosciences have?
$67.8 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Aura Biosciences (AURA) stock news?
Our latest story on Aura Biosciences, dated Aug 11, 2026: "Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029". The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients. Source.
Investor discussion: Aura Biosciences
Members talk about Aura Biosciences (AURA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Aura Biosciences, newest first. Each line links the filing it comes from.
Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,8.01,9.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AURA on TradingView.
SEC filings and registration
SEC name
Aura Biosciences, Inc.
CIK
1501796
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
AURA (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
80 GUEST STREET, BOSTON, MA, 02135
Phone
(617)500-8864
Shares outstanding
103,704,809 as of 2026-08-06 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Aura Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AURA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio